SCHEDULE OF ACCOUNTS RECEIVABLE (Details) - USD ($) |
Sep. 30, 2023 |
Dec. 31, 2022 |
---|---|---|
Receivables [Abstract] | ||
CyPath® Lung royalty income | $ 16,107 | $ 4,803 |
Laboratory services | 12,390 | |
Other receivables | 4,730 | 5,686 |
Purchased receivables from acquisition, net of collections | 791,852 | |
Net patient fees receivable | 249,088 | |
Histology fees | 31,854 | |
Medical director fees | 2,393 | |
Accounts and other receivable, net | $ 1,108,414 | $ 10,489 |
X | ||||||||||
- Definition Royalty income. No definition available.
|
X | ||||||||||
- Definition Histology fees. No definition available.
|
X | ||||||||||
- Definition Laboratory services. No definition available.
|
X | ||||||||||
- Definition Medical director fees. No definition available.
|
X | ||||||||||
- Definition Net patient fees receivable. No definition available.
|
X | ||||||||||
- Definition Purchased receivables from acquisition net of collections. No definition available.
|
X | ||||||||||
- Definition Amount due from parties in nontrade transactions, classified as other. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|